EGFR-vIII and MSS-specific CRC enriched in AdenoSig and unique Spp1 high TAM in mCRPC, showed a likelihood of benefits from the rational combination with A2AR inhibitors. The gene discussed is ADORA2A; the disease is colorectal carcinoma.